Clinical trials in Toulouse – page 19

1 521 clinical trials in Toulouse, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Toulouse at a glance

1 521

clinical trials

Research sites4

Quick filters

1 521 trials in Toulouse

Open in trial search

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Ascentage Pharma Group Inc.

Contact Research Centre

Brain neoplasm

Recruiting

Study of tarlatamab and temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

Study of tarlatamab and temozolomide combination treatment in adolescents and adults with high grade brain tumors

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Centre Leon Berard

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ambrisentan
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Cryoglobulinaemia

Recruiting

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Systemic scleroderma+3

Recruiting

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Artiva Biotherapeutics Inc.

Contact Research Centre

Craniocerebral injury

Recruiting

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Mannitol
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Myelodysplastic syndrome+1

Recruiting

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate
Sponsor:Groupe Francophone Des Myelodysplasies

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Chronic hepatitis B

Recruiting

Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

Registered drug

Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

Registered drug

France

Participants:18–64 years · 65+ years
Substances:ALG-000184
Sponsor:Aligos Therapeutics Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

TTR Amyloidosis Cardiomyopathy
Heart Failure Prevention
Cardiovascular Risk Management

02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

Head & Neck Squamous Cell Carcinoma
Gastric and GEJ Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer

03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

Frontotemporal Dementia
Essential Tremor
Traumatic Brain Injury
Multiple Sclerosis

04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

Crohn's Disease
Psoriatic Arthritis
Myasthenia Gravis
Idiopathic Pulmonary Fibrosis

Back to France All countries